Clinical Trials Arena on MSN9d
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adultsNeurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 ...
Neurocrine Biosciences announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, though the ...
Biosciences announced the initiation of a Phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and ...
In the last three months, 7 analysts have published ratings on Neurocrine Biosciences (NASDAQ:NBIX), offering a diverse range of perspectives from bullish to bearish. The table below offers a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback